Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 13 points (-0.1%) at 18,461 as of Wednesday, July 27, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,210 issues advancing vs. 1,692 declining with 152 unchanged.

The Drugs industry currently sits up 1.9% versus the S&P 500, which is down 0.3%. Top gainers within the industry include

Seattle Genetics

(

SGEN

), up 6.5%,

Celgene

(

CELG

), up 2.0%,

GlaxoSmithKline

(

GSK

), up 1.6%,

Allergan

(

AGN

), up 1.3% and

Vertex Pharmaceuticals

(

VRTX

), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Eli Lilly and

(

LLY

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Eli Lilly and is up $0.87 (1.1%) to $82.96 on light volume. Thus far, 1.5 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $82.15-$83.43 after having opened the day at $82.23 as compared to the previous trading day's close of $82.09.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $90.5 billion and is part of the health care sector. Shares are down 2.6% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Eli Lilly and

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Eli Lilly and Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Regeneron Pharmaceuticals

(

REGN

) is up $10.43 (2.6%) to $408.70 on average volume. Thus far, 451,031 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 900,400 shares. The stock has ranged in price between $399.00-$410.28 after having opened the day at $399.64 as compared to the previous trading day's close of $398.27.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $41.5 billion and is part of the health care sector. Shares are down 27.3% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Regeneron Pharmaceuticals a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Amgen

(

AMGN

) is up $1.43 (0.8%) to $169.10 on average volume. Thus far, 1.3 million shares of Amgen exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $167.44-$169.47 after having opened the day at $167.45 as compared to the previous trading day's close of $167.67.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. Amgen has a market cap of $125.1 billion and is part of the health care sector. Shares are up 3.3% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).